SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus

Cell Metabolism

Volumn 30, Issue 4, 2019, Pages 609-613

  Hess, David A ^a,b,d,e   Terenzi, Daniella C ^a,c   Trac, Justin Z ^a,b   Quan, Adrian ^a   Mason, Tamique ^a,b   Al Omran, Mohammed ^a,b,c   Bhatt, Deepak L ^f   Dhingra, Natasha ^a   Rotstein, Ori D ^a,c   Leiter, Lawrence A ^a,b,c   Zinman, Bernard ^c,g   Sabongui, Sandra ^a   Yan, Andrew T ^a,c   Teoh, Hwee ^a   Mazer, C David ^a,b,c   Connelly, Kim A ^a,c   Verma, Subodh ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CATALASE; CD133 ANTIGEN; CD34 ANTIGEN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SODIUM GLUCOSE COTRANSPORTER 2; BENZHYDRYL DERIVATIVE; CARDIOTONIC AGENT; GLUCOSIDE;

ADULT; AGED; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; ENZYME ACTIVITY; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; LETTER; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL; VASCULAR CELL LINE; VERY ELDERLY; CARDIOVASCULAR DISEASE; COMPLICATION; DRUG EFFECT; MIDDLE AGED; MYELOID PROGENITOR CELL; PHARMACOLOGY; PHYSIOLOGY; REGENERATION;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; MIDDLE AGED; MYELOID PROGENITOR CELLS; REGENERATION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85072570878     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2019.08.015     Document Type: Letter

References (15)

1. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., and Isner, J.M. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
2. Bonora, B.M., Cappellari, R., Albiero, M., Avogaro, A., and Fadini, G.P. (2018). Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 103, 3773-3782.
3. Capoccia, B.J., Robson, D.L., Levac, K.D., Maxwell, D.J., Hohm, S.A., Neelamkavil, M.J., Bell, G.I., Xenocostas, A., Link, D.C., Piwnica-Worms, D., et al. (2009). Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 113, 5340-5351.
4. Fadini, G.P., Rigato, M., Cappellari, R., Bonora, B.M., and Avogaro, A. (2017). Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes. Diabetes Care 40, 125-131.
5. Oelze, M., Kroller-Schon, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinssius, E., Agdauletova, S., et al. (2014). The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 9, e112394.
6. Putman, D.M., Liu, K.Y., Broughton, H.C., Bell, G.I., and Hess, D.A. (2012). Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote recovery from acute ischemic injury. Stem Cells 30, 2248-2260.
7. Sidibe, A., Ropraz, P., Jemelin, S., Emre, Y., Poittevin, M., Pocard, M., Bradfield, P.F., and Imhof, B.A. (2018). Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours. Nat. Commun. 9, 355.
8. Spiller, K.L., Nassiri, S., Witherel, C.E., Anfang, R.R., Ng, J., Nakazawa, K.R., Yu, T., and Vunjak-Novakovic, G. (2015). Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. Biomaterials 37, 194-207.
9. Storms, R.W., Trujillo, A.P., Springer, J.B., Shah, L., Colvin, O.M., Ludeman, S.M., and Smith, C. (1999). Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc. Natl. Acad. Sci. USA 96, 9118-9123.
10. Terenzi, D.C., Al-Omran, M., Quan, A., Teoh, H., Verma, S., and Hess, D.A. (2018). Circulating pro-vascular progenitor cell depletion during type 2 diabetes: translational insights into the prevention of ischemic complications in diabetes. JACC Basic Transl. Sci. 4, 98-112.
11. Terenzi, D.C., Trac, J.Z., Teoh, H., Gerstein, H.C., Bhatt, D.L., Al-Omran, M., Verma, S., and Hess, D.A. (2019). Vascular regenerative cell exhaustion in diabetes: translational opportunities to mitigate cardiometabolic risk. Trends Mol. Med. 25, 640-655.
12. Verma, S., Mazer, C.D., Al-Omran, M., Inzucchi, S.E., Fitchett, D., Hehnke, U., George, J.T., and Zinman, B. (2018). Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137, 405-407.
13. Verma, S., Mazer, C.D., Yan, A.T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M.E., Fitchett, D., et al. (2019). Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease. The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation, in press.
14. Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Furtado, R.H.M., et al. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31-39.
15. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., et al.; EMPA-REG OUTCOME Investigators (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128.